ENTPD1 and neoplasm: With the help of scRNA-seq, TCR-seq, cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) and other technologies, researchers are able to comprehensively characterize T cells rapidly in a variety of tumors using a panel of CXCL13, ENTPD1(CD39) and CD200, the high-frequency molecular features of tumor neoantigen specific T (Tas) cells.